Clinical Trial Update: BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of a BCMA-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma and plasmacytoid lymphoma is currently recruiting, sponsored by iCell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasmacytoid Lymphoma

Drugs mentioned

• BCMA-CD19 CAR-T (BCMA-CD19 chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: iCell Gene Therapeutics | Conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING